Uncovering the mechanism of resveratrol in the treatment of diabetic kidney disease based on network pharmacology, molecular docking, and experimental validation

Background Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol (RES) for the treatment of DKD is accumulating. However, comprehensive therapeutic targets and underlying mechanisms through which RES exerts...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of translational medicine Jg. 21; H. 1; S. 380 - 14
Hauptverfasser: Chen, Shengnan, Li, Bo, Chen, Lei, Jiang, Hongli
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London BioMed Central 12.06.2023
BioMed Central Ltd
Springer Nature B.V
BMC
Schlagworte:
AKT1 protein
Aldehyde Reductase
Analysis
Association analysis
Bioinformatics
Biomedical and Life Sciences
Biomedicine
Care and treatment
Computer simulation
Diabetes
Diabetes Mellitus
Diabetic kidney disease
Diabetic Nephropathies
Diabetic nephropathy
Diagnosis
Dietary supplements
Dosage and administration
ESR1 protein
Experimental validation
Gelatinase A
Gelatinase B
Gene expression
Gene set enrichment analysis
Genes
Genomics
Glucose
Humans
Kidney diseases
Matrix Metalloproteinase 9
Medicine/Public Health
Molecular docking
Molecular Docking Simulation
Network Pharmacology
Nutrition & metabolism
Peroxisome proliferator-activated receptors
Pharmacology
Phytochemicals
PPAR gamma
Proteins
Reproducibility of Results
Resveratrol
Software
Therapeutic applications
Therapeutic targets
China
United States > US
Experimental validation
Network pharmacology
Molecular docking
Resveratrol
Diabetic kidney disease
ISSN:1479-5876, 1479-5876
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Background Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol (RES) for the treatment of DKD is accumulating. However, comprehensive therapeutic targets and underlying mechanisms through which RES exerts its effects against DKD are limited. Methods Drug targets of RES were obtained from Drugbank and SwissTargetPrediction Databases. Disease targets of DKD were obtained from DisGeNET, Genecards, and Therapeutic Target Database. Therapeutic targets for RES against DKD were identified by intersecting the drug targets and disease targets. GO functional enrichment analysis, KEGG pathway analysis, and disease association analysis were performed using the DAVID database and visualized by Cytoscape software. Molecular docking validation of the binding capacity between RES and targets was performed by UCSF Chimera software and SwissDock webserver. The high glucose (HG)-induced podocyte injury model, RT-qPCR, and western blot were used to verify the reliability of the effects of RES on target proteins. Results After the intersection of the 86 drug targets and 566 disease targets, 25 therapeutic targets for RES against DKD were obtained. And the target proteins were classified into 6 functional categories. A total of 11 cellular components terms and 27 diseases, and the top 20 enriched biological processes, molecular functions, and KEGG pathways potentially involved in the RES action against DKD were recorded. Molecular docking studies showed that RES had a strong binding affinity toward PPARA, ESR1, SLC2A1, SHBG, AR, AKR1B1, PPARG, IGF1R, RELA, PIK3CA, MMP9, AKT1, INSR, MMP2, TTR, and CYP2C9 domains. The HG-induced podocyte injury model was successfully constructed and validated by RT-qPCR and western blot. RES treatment was able to reverse the abnormal gene expression of PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR. Conclusions RES may target PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR domains to act as a therapeutic agent for DKD. These findings comprehensively reveal the potential therapeutic targets for RES against DKD and provide theoretical bases for the clinical application of RES in the treatment of DKD.
AbstractList Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol (RES) for the treatment of DKD is accumulating. However, comprehensive therapeutic targets and underlying mechanisms through which RES exerts its effects against DKD are limited.BACKGROUNDDiabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol (RES) for the treatment of DKD is accumulating. However, comprehensive therapeutic targets and underlying mechanisms through which RES exerts its effects against DKD are limited.Drug targets of RES were obtained from Drugbank and SwissTargetPrediction Databases. Disease targets of DKD were obtained from DisGeNET, Genecards, and Therapeutic Target Database. Therapeutic targets for RES against DKD were identified by intersecting the drug targets and disease targets. GO functional enrichment analysis, KEGG pathway analysis, and disease association analysis were performed using the DAVID database and visualized by Cytoscape software. Molecular docking validation of the binding capacity between RES and targets was performed by UCSF Chimera software and SwissDock webserver. The high glucose (HG)-induced podocyte injury model, RT-qPCR, and western blot were used to verify the reliability of the effects of RES on target proteins.METHODSDrug targets of RES were obtained from Drugbank and SwissTargetPrediction Databases. Disease targets of DKD were obtained from DisGeNET, Genecards, and Therapeutic Target Database. Therapeutic targets for RES against DKD were identified by intersecting the drug targets and disease targets. GO functional enrichment analysis, KEGG pathway analysis, and disease association analysis were performed using the DAVID database and visualized by Cytoscape software. Molecular docking validation of the binding capacity between RES and targets was performed by UCSF Chimera software and SwissDock webserver. The high glucose (HG)-induced podocyte injury model, RT-qPCR, and western blot were used to verify the reliability of the effects of RES on target proteins.After the intersection of the 86 drug targets and 566 disease targets, 25 therapeutic targets for RES against DKD were obtained. And the target proteins were classified into 6 functional categories. A total of 11 cellular components terms and 27 diseases, and the top 20 enriched biological processes, molecular functions, and KEGG pathways potentially involved in the RES action against DKD were recorded. Molecular docking studies showed that RES had a strong binding affinity toward PPARA, ESR1, SLC2A1, SHBG, AR, AKR1B1, PPARG, IGF1R, RELA, PIK3CA, MMP9, AKT1, INSR, MMP2, TTR, and CYP2C9 domains. The HG-induced podocyte injury model was successfully constructed and validated by RT-qPCR and western blot. RES treatment was able to reverse the abnormal gene expression of PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR.RESULTSAfter the intersection of the 86 drug targets and 566 disease targets, 25 therapeutic targets for RES against DKD were obtained. And the target proteins were classified into 6 functional categories. A total of 11 cellular components terms and 27 diseases, and the top 20 enriched biological processes, molecular functions, and KEGG pathways potentially involved in the RES action against DKD were recorded. Molecular docking studies showed that RES had a strong binding affinity toward PPARA, ESR1, SLC2A1, SHBG, AR, AKR1B1, PPARG, IGF1R, RELA, PIK3CA, MMP9, AKT1, INSR, MMP2, TTR, and CYP2C9 domains. The HG-induced podocyte injury model was successfully constructed and validated by RT-qPCR and western blot. RES treatment was able to reverse the abnormal gene expression of PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR.RES may target PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR domains to act as a therapeutic agent for DKD. These findings comprehensively reveal the potential therapeutic targets for RES against DKD and provide theoretical bases for the clinical application of RES in the treatment of DKD.CONCLUSIONSRES may target PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR domains to act as a therapeutic agent for DKD. These findings comprehensively reveal the potential therapeutic targets for RES against DKD and provide theoretical bases for the clinical application of RES in the treatment of DKD.
Background Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol (RES) for the treatment of DKD is accumulating. However, comprehensive therapeutic targets and underlying mechanisms through which RES exerts its effects against DKD are limited. Methods Drug targets of RES were obtained from Drugbank and SwissTargetPrediction Databases. Disease targets of DKD were obtained from DisGeNET, Genecards, and Therapeutic Target Database. Therapeutic targets for RES against DKD were identified by intersecting the drug targets and disease targets. GO functional enrichment analysis, KEGG pathway analysis, and disease association analysis were performed using the DAVID database and visualized by Cytoscape software. Molecular docking validation of the binding capacity between RES and targets was performed by UCSF Chimera software and SwissDock webserver. The high glucose (HG)-induced podocyte injury model, RT-qPCR, and western blot were used to verify the reliability of the effects of RES on target proteins. Results After the intersection of the 86 drug targets and 566 disease targets, 25 therapeutic targets for RES against DKD were obtained. And the target proteins were classified into 6 functional categories. A total of 11 cellular components terms and 27 diseases, and the top 20 enriched biological processes, molecular functions, and KEGG pathways potentially involved in the RES action against DKD were recorded. Molecular docking studies showed that RES had a strong binding affinity toward PPARA, ESR1, SLC2A1, SHBG, AR, AKR1B1, PPARG, IGF1R, RELA, PIK3CA, MMP9, AKT1, INSR, MMP2, TTR, and CYP2C9 domains. The HG-induced podocyte injury model was successfully constructed and validated by RT-qPCR and western blot. RES treatment was able to reverse the abnormal gene expression of PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR. Conclusions RES may target PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR domains to act as a therapeutic agent for DKD. These findings comprehensively reveal the potential therapeutic targets for RES against DKD and provide theoretical bases for the clinical application of RES in the treatment of DKD.
Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol (RES) for the treatment of DKD is accumulating. However, comprehensive therapeutic targets and underlying mechanisms through which RES exerts its effects against DKD are limited. Drug targets of RES were obtained from Drugbank and SwissTargetPrediction Databases. Disease targets of DKD were obtained from DisGeNET, Genecards, and Therapeutic Target Database. Therapeutic targets for RES against DKD were identified by intersecting the drug targets and disease targets. GO functional enrichment analysis, KEGG pathway analysis, and disease association analysis were performed using the DAVID database and visualized by Cytoscape software. Molecular docking validation of the binding capacity between RES and targets was performed by UCSF Chimera software and SwissDock webserver. The high glucose (HG)-induced podocyte injury model, RT-qPCR, and western blot were used to verify the reliability of the effects of RES on target proteins. After the intersection of the 86 drug targets and 566 disease targets, 25 therapeutic targets for RES against DKD were obtained. And the target proteins were classified into 6 functional categories. A total of 11 cellular components terms and 27 diseases, and the top 20 enriched biological processes, molecular functions, and KEGG pathways potentially involved in the RES action against DKD were recorded. Molecular docking studies showed that RES had a strong binding affinity toward PPARA, ESR1, SLC2A1, SHBG, AR, AKR1B1, PPARG, IGF1R, RELA, PIK3CA, MMP9, AKT1, INSR, MMP2, TTR, and CYP2C9 domains. The HG-induced podocyte injury model was successfully constructed and validated by RT-qPCR and western blot. RES treatment was able to reverse the abnormal gene expression of PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR. RES may target PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR domains to act as a therapeutic agent for DKD. These findings comprehensively reveal the potential therapeutic targets for RES against DKD and provide theoretical bases for the clinical application of RES in the treatment of DKD.
BackgroundDiabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol (RES) for the treatment of DKD is accumulating. However, comprehensive therapeutic targets and underlying mechanisms through which RES exerts its effects against DKD are limited.MethodsDrug targets of RES were obtained from Drugbank and SwissTargetPrediction Databases. Disease targets of DKD were obtained from DisGeNET, Genecards, and Therapeutic Target Database. Therapeutic targets for RES against DKD were identified by intersecting the drug targets and disease targets. GO functional enrichment analysis, KEGG pathway analysis, and disease association analysis were performed using the DAVID database and visualized by Cytoscape software. Molecular docking validation of the binding capacity between RES and targets was performed by UCSF Chimera software and SwissDock webserver. The high glucose (HG)-induced podocyte injury model, RT-qPCR, and western blot were used to verify the reliability of the effects of RES on target proteins.ResultsAfter the intersection of the 86 drug targets and 566 disease targets, 25 therapeutic targets for RES against DKD were obtained. And the target proteins were classified into 6 functional categories. A total of 11 cellular components terms and 27 diseases, and the top 20 enriched biological processes, molecular functions, and KEGG pathways potentially involved in the RES action against DKD were recorded. Molecular docking studies showed that RES had a strong binding affinity toward PPARA, ESR1, SLC2A1, SHBG, AR, AKR1B1, PPARG, IGF1R, RELA, PIK3CA, MMP9, AKT1, INSR, MMP2, TTR, and CYP2C9 domains. The HG-induced podocyte injury model was successfully constructed and validated by RT-qPCR and western blot. RES treatment was able to reverse the abnormal gene expression of PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR.ConclusionsRES may target PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR domains to act as a therapeutic agent for DKD. These findings comprehensively reveal the potential therapeutic targets for RES against DKD and provide theoretical bases for the clinical application of RES in the treatment of DKD.
Background Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol (RES) for the treatment of DKD is accumulating. However, comprehensive therapeutic targets and underlying mechanisms through which RES exerts its effects against DKD are limited. Methods Drug targets of RES were obtained from Drugbank and SwissTargetPrediction Databases. Disease targets of DKD were obtained from DisGeNET, Genecards, and Therapeutic Target Database. Therapeutic targets for RES against DKD were identified by intersecting the drug targets and disease targets. GO functional enrichment analysis, KEGG pathway analysis, and disease association analysis were performed using the DAVID database and visualized by Cytoscape software. Molecular docking validation of the binding capacity between RES and targets was performed by UCSF Chimera software and SwissDock webserver. The high glucose (HG)-induced podocyte injury model, RT-qPCR, and western blot were used to verify the reliability of the effects of RES on target proteins. Results After the intersection of the 86 drug targets and 566 disease targets, 25 therapeutic targets for RES against DKD were obtained. And the target proteins were classified into 6 functional categories. A total of 11 cellular components terms and 27 diseases, and the top 20 enriched biological processes, molecular functions, and KEGG pathways potentially involved in the RES action against DKD were recorded. Molecular docking studies showed that RES had a strong binding affinity toward PPARA, ESR1, SLC2A1, SHBG, AR, AKR1B1, PPARG, IGF1R, RELA, PIK3CA, MMP9, AKT1, INSR, MMP2, TTR, and CYP2C9 domains. The HG-induced podocyte injury model was successfully constructed and validated by RT-qPCR and western blot. RES treatment was able to reverse the abnormal gene expression of PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR. Conclusions RES may target PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR domains to act as a therapeutic agent for DKD. These findings comprehensively reveal the potential therapeutic targets for RES against DKD and provide theoretical bases for the clinical application of RES in the treatment of DKD. Keywords: Resveratrol, Diabetic kidney disease, Network pharmacology, Molecular docking, Experimental validation
Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol (RES) for the treatment of DKD is accumulating. However, comprehensive therapeutic targets and underlying mechanisms through which RES exerts its effects against DKD are limited. Drug targets of RES were obtained from Drugbank and SwissTargetPrediction Databases. Disease targets of DKD were obtained from DisGeNET, Genecards, and Therapeutic Target Database. Therapeutic targets for RES against DKD were identified by intersecting the drug targets and disease targets. GO functional enrichment analysis, KEGG pathway analysis, and disease association analysis were performed using the DAVID database and visualized by Cytoscape software. Molecular docking validation of the binding capacity between RES and targets was performed by UCSF Chimera software and SwissDock webserver. The high glucose (HG)-induced podocyte injury model, RT-qPCR, and western blot were used to verify the reliability of the effects of RES on target proteins. After the intersection of the 86 drug targets and 566 disease targets, 25 therapeutic targets for RES against DKD were obtained. And the target proteins were classified into 6 functional categories. A total of 11 cellular components terms and 27 diseases, and the top 20 enriched biological processes, molecular functions, and KEGG pathways potentially involved in the RES action against DKD were recorded. Molecular docking studies showed that RES had a strong binding affinity toward PPARA, ESR1, SLC2A1, SHBG, AR, AKR1B1, PPARG, IGF1R, RELA, PIK3CA, MMP9, AKT1, INSR, MMP2, TTR, and CYP2C9 domains. The HG-induced podocyte injury model was successfully constructed and validated by RT-qPCR and western blot. RES treatment was able to reverse the abnormal gene expression of PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR. RES may target PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR domains to act as a therapeutic agent for DKD. These findings comprehensively reveal the potential therapeutic targets for RES against DKD and provide theoretical bases for the clinical application of RES in the treatment of DKD.
Abstract Background Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol (RES) for the treatment of DKD is accumulating. However, comprehensive therapeutic targets and underlying mechanisms through which RES exerts its effects against DKD are limited. Methods Drug targets of RES were obtained from Drugbank and SwissTargetPrediction Databases. Disease targets of DKD were obtained from DisGeNET, Genecards, and Therapeutic Target Database. Therapeutic targets for RES against DKD were identified by intersecting the drug targets and disease targets. GO functional enrichment analysis, KEGG pathway analysis, and disease association analysis were performed using the DAVID database and visualized by Cytoscape software. Molecular docking validation of the binding capacity between RES and targets was performed by UCSF Chimera software and SwissDock webserver. The high glucose (HG)-induced podocyte injury model, RT-qPCR, and western blot were used to verify the reliability of the effects of RES on target proteins. Results After the intersection of the 86 drug targets and 566 disease targets, 25 therapeutic targets for RES against DKD were obtained. And the target proteins were classified into 6 functional categories. A total of 11 cellular components terms and 27 diseases, and the top 20 enriched biological processes, molecular functions, and KEGG pathways potentially involved in the RES action against DKD were recorded. Molecular docking studies showed that RES had a strong binding affinity toward PPARA, ESR1, SLC2A1, SHBG, AR, AKR1B1, PPARG, IGF1R, RELA, PIK3CA, MMP9, AKT1, INSR, MMP2, TTR, and CYP2C9 domains. The HG-induced podocyte injury model was successfully constructed and validated by RT-qPCR and western blot. RES treatment was able to reverse the abnormal gene expression of PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR. Conclusions RES may target PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR domains to act as a therapeutic agent for DKD. These findings comprehensively reveal the potential therapeutic targets for RES against DKD and provide theoretical bases for the clinical application of RES in the treatment of DKD.
ArticleNumber 380
Audience Academic
Author Li, Bo
Chen, Shengnan
Chen, Lei
Jiang, Hongli
Author_xml – sequence: 1
  givenname: Shengnan
  surname: Chen
  fullname: Chen, Shengnan
  organization: Department of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi’an Jiaotong University
– sequence: 2
  givenname: Bo
  surname: Li
  fullname: Li, Bo
  organization: Department of Nephrology, Ningxia Medical University Affiliated People’s Hospital of Autonomous Region of Ningxia
– sequence: 3
  givenname: Lei
  surname: Chen
  fullname: Chen, Lei
  organization: Department of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi’an Jiaotong University
– sequence: 4
  givenname: Hongli
  orcidid: 0000-0001-9262-6112
  surname: Jiang
  fullname: Jiang, Hongli
  email: j92106@sina.com
  organization: Department of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi’an Jiaotong University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37308949$$D View this record in MEDLINE/PubMed
BookMark eNp9kstu1DAUhiNURC_wAiyQJTYsOsW3OMkKVRWXSpXY0LV1Yp_MeJrYg52ZMo_Dm-LMtNBWqInkJD7__9nH-Y-LAx88FsVbRs8Yq9XHxHijqhnlYkYlF3l8URwxWTWzsq7UwYP3w-I4pSWlXJayeVUcikrQupHNUfH72puwwej8nIwLJAOaBXiXBhI6EjHlEowx9MT5XX2MCOOAfpzq1kGLozPkxlmP2_ydEBKSNg-WBE88jrch3pDVAuIAJvRhvj0lQ-jRrHuIxAZzk1c-JeAtwV-rvI-JDT3ZQO8sjC7418XLDvqEb-6eJ8X1l88_Lr7Nrr5_vbw4v5oZRetx1qmOtyDRYCU4txTKqrPcQteiVQIEgkIqrKnRUCxp0_K2EaxkUglDFSpxUlzuuTbAUq_yTiBudQCndxMhzjXE3GyPGo1UNaMSKRXSiApQWcgXQ2gkY2VmfdqzVut2QGtyTxH6R9DHFe8Weh42mlFe1k0zET7cEWL4ucY06sElg30PHsM6aV7zsqSUVTxL3z-RLsM6-nxWk6pirFI74J1qDrkD57uQFzYTVJ9XZRZSKVlWnf1HlW-LgzM5fp3L848M7x52-rfF-4RlQb0XmBhSithp48bdj81k1-eO9RRmvQ-zzmHWuzBrmq38ifWe_qxJ7E1pNYUa47_TeMb1B_KCCeU
CitedBy_id crossref_primary_10_1016_j_fbio_2024_103974
crossref_primary_10_1155_jfbc_5801408
crossref_primary_10_3390_plants14142132
crossref_primary_10_3390_antiox13091104
crossref_primary_10_3390_cimb47080619
crossref_primary_10_1016_j_vascn_2025_108381
crossref_primary_10_1186_s10020_025_01096_7
crossref_primary_10_1038_s41598_025_16380_z
crossref_primary_10_3389_fnagi_2025_1568002
crossref_primary_10_1177_1934578X241277543
crossref_primary_10_3390_cimb46080531
crossref_primary_10_1002_jsfa_13664
crossref_primary_10_1186_s13020_023_00810_z
crossref_primary_10_1016_j_phymed_2024_155817
crossref_primary_10_1007_s10142_024_01513_w
crossref_primary_10_1007_s11064_025_04411_0
crossref_primary_10_1007_s12010_025_05215_2
crossref_primary_10_4239_wjd_v16_i8_110285
crossref_primary_10_1016_j_jep_2025_119728
crossref_primary_10_1007_s10616_025_00748_0
crossref_primary_10_1016_j_jare_2025_04_022
crossref_primary_10_1016_j_jep_2024_119023
crossref_primary_10_1038_s41598_025_17067_1
crossref_primary_10_1016_j_cellsig_2024_111276
crossref_primary_10_2147_DMSO_S523784
crossref_primary_10_1016_j_bbrc_2025_151434
crossref_primary_10_1016_j_jep_2025_120145
crossref_primary_10_1016_j_ecoenv_2025_118244
crossref_primary_10_1186_s12935_025_03893_w
crossref_primary_10_1016_j_jff_2025_106874
crossref_primary_10_1016_j_ijbiomac_2024_131739
crossref_primary_10_1002_biof_70018
crossref_primary_10_1186_s10020_024_01001_8
crossref_primary_10_1155_2023_8871677
crossref_primary_10_1016_j_phrs_2024_107381
crossref_primary_10_2174_0118715303331820240820072804
crossref_primary_10_1007_s11030_024_11004_6
crossref_primary_10_3389_fphar_2024_1379821
crossref_primary_10_3390_ijms241813914
crossref_primary_10_1186_s10020_024_01033_0
crossref_primary_10_1016_j_phanu_2025_100439
crossref_primary_10_1016_j_phymed_2024_156092
crossref_primary_10_1016_j_ejmech_2024_116335
crossref_primary_10_1016_j_lfs_2025_123881
crossref_primary_10_1038_s41598_025_11312_3
crossref_primary_10_2147_DDDT_S521265
crossref_primary_10_1155_2024_2271214
crossref_primary_10_3390_ph18010012
crossref_primary_10_3389_fmolb_2025_1541440
crossref_primary_10_1002_jcb_30655
crossref_primary_10_1016_j_ejmech_2025_118003
crossref_primary_10_1016_j_taap_2024_117212
crossref_primary_10_1002_ptr_8319
crossref_primary_10_1016_j_fbio_2024_104407
Cites_doi 10.3892/or.2014.3192
10.1002/biof.1531
10.1016/j.ejphar.2018.08.035
10.1371/journal.pone.0101070
10.1038/ki.2014.67
10.2337/diab.39.2.129
10.1016/j.semcancer.2020.06.014
10.3390/ijms21207648
10.3389/fendo.2022.892860
10.1039/C3FO60236B
10.1016/j.redox.2021.102033
10.1007/s00018-022-04551-4
10.1093/nar/gkz382
10.1017/S0007114511000316
10.1093/nar/gky1131
10.3390/ijms22137060
10.3390/biology11091324
10.1093/nar/gkr366
10.3892/ijmm_00000416
10.3389/fphar.2019.01185
10.1186/1471-2407-10-238
10.1111/jcmm.15581
10.1080/10408444.2020.1762538
10.1016/j.biopha.2019.109767
10.1152/ajpendo.00071.2019
10.1111/cns.12194
10.1093/nar/gkx1037
10.1016/j.cca.2019.09.010
10.3389/fgene.2021.767654
10.3390/ph14080806
10.1038/s41467-019-12433-w
10.1093/nar/gku377
10.1016/j.fct.2013.06.037
10.1038/s41598-017-12509-x
10.1039/D1SC05613A
10.1039/D0FO02387F
10.1093/nar/28.1.235
10.1113/JP278082
10.1093/ndt/gfs387
10.1093/database/baq020
10.3389/fbioe.2020.619252
10.1038/aps.2015.128
10.1097/FJC.0000000000000504
10.1016/j.ymthe.2022.01.002
10.1007/s13300-020-00843-9
10.3390/pharmaceutics13060781
10.3390/antiox9040273
10.1016/j.rbmo.2020.10.003
10.1172/JCI72271
10.1210/endo.139.3.5832
10.1016/j.diabet.2018.05.010
10.1016/j.biochi.2020.01.007
10.1007/s11033-012-1728-3
10.1093/nar/gkv951
10.1186/s12920-023-01519-6
10.1002/jcp.27306
10.1002/cbic.201300754
10.1186/s12967-016-0922-9
10.1053/j.ackd.2017.10.011
10.2337/dc14-1296
10.3390/biom9080362
10.1016/j.gendis.2018.06.001
10.1093/nar/gkaa1106
10.3389/fphar.2020.00425
10.1186/1758-2946-3-33
10.1093/nar/30.1.412
10.1186/gb-2003-4-5-p3
10.1093/nar/gkaa1100
10.1038/s41581-020-0309-2
ContentType Journal Article
Copyright The Author(s) 2023
2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s12967-023-04233-0
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


Publicly Available Content Database

MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database (subscription)
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 14
ExternalDocumentID oai_doaj_org_article_ec468104e0034c37ae6daaaa1ea94115
PMC10258995
A752820441
37308949
10_1186_s12967_023_04233_0
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations China
United States--US
GeographicLocations_xml – name: China
– name: United States--US
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 82170755
  funderid: http://dx.doi.org/10.13039/501100001809
– fundername: ;
  grantid: 82170755
GroupedDBID ---
0R~
29L
2WC
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
AAYXX
AFFHD
CITATION
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
7X8
5PM
ID FETCH-LOGICAL-c608t-f6f2ba4ece7322d0a57fd2dafbed63a3ea6e03dc8ec0e509b2b93151463c06e63
IEDL.DBID BENPR
ISICitedReferencesCount 71
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001007559500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1479-5876
IngestDate Tue Oct 14 19:09:46 EDT 2025
Tue Nov 04 02:06:45 EST 2025
Sun Nov 09 09:36:14 EST 2025
Sun Oct 19 00:08:39 EDT 2025
Tue Nov 11 10:19:39 EST 2025
Tue Nov 04 17:17:33 EST 2025
Thu May 22 04:23:24 EDT 2025
Sat Nov 29 04:16:10 EST 2025
Tue Nov 18 22:34:08 EST 2025
Sat Sep 06 07:28:44 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Experimental validation
Network pharmacology
Molecular docking
Resveratrol
Diabetic kidney disease
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c608t-f6f2ba4ece7322d0a57fd2dafbed63a3ea6e03dc8ec0e509b2b93151463c06e63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-9262-6112
OpenAccessLink https://www.proquest.com/docview/2827117695?pq-origsite=%requestingapplication%
PMID 37308949
PQID 2827117695
PQPubID 43076
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_ec468104e0034c37ae6daaaa1ea94115
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10258995
proquest_miscellaneous_2825500172
proquest_journals_2827117695
gale_infotracmisc_A752820441
gale_infotracacademiconefile_A752820441
pubmed_primary_37308949
crossref_citationtrail_10_1186_s12967_023_04233_0
crossref_primary_10_1186_s12967_023_04233_0
springer_journals_10_1186_s12967_023_04233_0
PublicationCentury 2000
PublicationDate 2023-06-12
PublicationDateYYYYMMDD 2023-06-12
PublicationDate_xml – month: 06
  year: 2023
  text: 2023-06-12
  day: 12
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Journal of translational medicine
PublicationTitleAbbrev J Transl Med
PublicationTitleAlternate J Transl Med
PublicationYear 2023
Publisher BioMed Central
BioMed Central Ltd
Springer Nature B.V
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: Springer Nature B.V
– name: BMC
References Z Wu (4233_CR17) 2022; 13
S Chen (4233_CR37) 2023; 16
R Khayami (4233_CR52) 2020; 24
X Pan (4233_CR4) 2022; 13
E Khatoon (4233_CR10) 2022; 80
UniProt Consortium (4233_CR33) 2021; 49
J Vanamala (4233_CR57) 2010; 10
K Kushwaha (4233_CR9) 2020; 170
RJ Qasem (4233_CR51) 2020; 50
M Kadela-Tomanek (4233_CR41) 2021; 13
P Brasnyó (4233_CR14) 2011; 106
R Dong (4233_CR55) 2019; 317
A Grosdidier (4233_CR35) 2011; 39
A Sattarinezhad (4233_CR13) 2019; 45
HS Park (4233_CR44) 2016; 14
C Ohlsson (4233_CR58) 1998; 139
M Safran (4233_CR25) 2010; 2010
YL Kong (4233_CR56) 2016; 37
N Razali (4233_CR65) 2018; 838
C Tang (4233_CR6) 2020; 16
K Reidy (4233_CR20) 2014; 124
X Huang (4233_CR39) 2021; 22
T Zhang (4233_CR47) 2019; 234
Y Li (4233_CR48) 2021; 42
SY Li (4233_CR60) 2014; 86
J Walker (4233_CR62) 2014; 5
DN Koye (4233_CR3) 2018; 25
JL Zhu (4233_CR49) 2019; 499
A Daina (4233_CR23) 2019; 47
J Piñero (4233_CR24) 2020; 48
H Mi (4233_CR27) 2021; 49
D Szklarczyk (4233_CR28) 2019; 47
TC Hsieh (4233_CR72) 2014; 9
Y Hou (4233_CR70) 2018; 5
Z Wu (4233_CR71) 2017; 70
GM Brawerman (4233_CR42) 2019; 597
X Chen (4233_CR26) 2002; 30
RC Yang (4233_CR36) 2013; 33
J Blahova (4233_CR8) 2021; 14
A Roborel de Climens (4233_CR7) 2020; 11
G Li (4233_CR59) 2021; 12
S Seino (4233_CR68) 1990; 39
YS Kim (4233_CR61) 2012; 39
MK Sangeetha (4233_CR38) 2013; 59
CC Huang (4233_CR32) 2014; 42
L Jiang (4233_CR19) 2022; 30
F Hajizadeh-Sharafabad (4233_CR46) 2019; 45
EJ Gweon (4233_CR64) 2014; 32
F Balestri (4233_CR53) 2022; 11
Y Zhong (4233_CR21) 2019; 10
DS Wishart (4233_CR22) 2017; 46
S Kim (4233_CR30) 2016; 44
Y Zhang (4233_CR45) 2010; 25
DJ Magliano (4233_CR1) 2021
KR Tuttle (4233_CR2) 2014; 37
S Zhou (4233_CR15) 2020; 11
W-Y Lee (4233_CR18) 2019; 9
M Behroozaghdam (4233_CR12) 2022; 79
M McKenna (4233_CR67) 2020; 8
DD Huang (4233_CR11) 2020; 125
W Guo (4233_CR16) 2019; 10
C Saez-Lopez (4233_CR50) 2017; 7
NM O'Boyle (4233_CR31) 2011; 3
X Dai (4233_CR5) 2021; 45
X Sun (4233_CR69) 2021; 12
G Dennis (4233_CR29) 2003; 4
HM Berman (4233_CR34) 2000; 28
AW Shao (4233_CR63) 2014; 20
Y Takamiya (4233_CR66) 2013; 28
NA Murugan (4233_CR40) 2020; 21
E Calleri (4233_CR43) 2014; 15
T-T Wu (4233_CR54) 2020; 9
References_xml – volume: 32
  start-page: 71
  year: 2014
  ident: 4233_CR64
  publication-title: Oncol Rep
  doi: 10.3892/or.2014.3192
– volume: 45
  start-page: 651
  year: 2019
  ident: 4233_CR46
  publication-title: BioFactors
  doi: 10.1002/biof.1531
– volume: 838
  start-page: 1
  year: 2018
  ident: 4233_CR65
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2018.08.035
– volume: 9
  year: 2014
  ident: 4233_CR72
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0101070
– volume: 86
  start-page: 358
  year: 2014
  ident: 4233_CR60
  publication-title: Kidney Int
  doi: 10.1038/ki.2014.67
– volume: 39
  start-page: 129
  year: 1990
  ident: 4233_CR68
  publication-title: Diabetes
  doi: 10.2337/diab.39.2.129
– volume: 80
  start-page: 306
  year: 2022
  ident: 4233_CR10
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2020.06.014
– volume: 21
  start-page: 7648
  year: 2020
  ident: 4233_CR40
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21207648
– volume: 13
  year: 2022
  ident: 4233_CR4
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/fendo.2022.892860
– volume: 5
  start-page: 74
  year: 2014
  ident: 4233_CR62
  publication-title: Food Funct
  doi: 10.1039/C3FO60236B
– volume: 45
  year: 2021
  ident: 4233_CR5
  publication-title: Redox Biol
  doi: 10.1016/j.redox.2021.102033
– volume: 79
  start-page: 539
  year: 2022
  ident: 4233_CR12
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-022-04551-4
– volume: 47
  start-page: W357
  year: 2019
  ident: 4233_CR23
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkz382
– volume: 106
  start-page: 383
  year: 2011
  ident: 4233_CR14
  publication-title: Br J Nutr
  doi: 10.1017/S0007114511000316
– volume: 47
  start-page: D607
  year: 2019
  ident: 4233_CR28
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gky1131
– volume: 22
  start-page: 7060
  year: 2021
  ident: 4233_CR39
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22137060
– volume: 11
  start-page: 1324
  year: 2022
  ident: 4233_CR53
  publication-title: Biology
  doi: 10.3390/biology11091324
– volume: 39
  start-page: W270
  year: 2011
  ident: 4233_CR35
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkr366
– volume: 25
  start-page: 729
  year: 2010
  ident: 4233_CR45
  publication-title: Int J Mol Med
  doi: 10.3892/ijmm_00000416
– volume: 10
  start-page: 1185
  year: 2019
  ident: 4233_CR16
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2019.01185
– volume: 10
  start-page: 238
  year: 2010
  ident: 4233_CR57
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-10-238
– volume: 24
  start-page: 8890
  year: 2020
  ident: 4233_CR52
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.15581
– volume: 50
  start-page: 439
  year: 2020
  ident: 4233_CR51
  publication-title: Crit Rev Toxicol
  doi: 10.1080/10408444.2020.1762538
– volume: 125
  year: 2020
  ident: 4233_CR11
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2019.109767
– volume: 317
  start-page: E686
  year: 2019
  ident: 4233_CR55
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00071.2019
– volume: 48
  start-page: D845
  year: 2020
  ident: 4233_CR24
  publication-title: Nucleic Acids Res
– volume: 20
  start-page: 182
  year: 2014
  ident: 4233_CR63
  publication-title: CNS Neurosci Ther
  doi: 10.1111/cns.12194
– volume: 46
  start-page: D1074
  year: 2017
  ident: 4233_CR22
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx1037
– volume: 499
  start-page: 142
  year: 2019
  ident: 4233_CR49
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2019.09.010
– volume: 12
  year: 2021
  ident: 4233_CR59
  publication-title: Front Genet
  doi: 10.3389/fgene.2021.767654
– volume: 14
  start-page: 806
  year: 2021
  ident: 4233_CR8
  publication-title: Pharmaceuticals
  doi: 10.3390/ph14080806
– volume: 10
  start-page: 4523
  year: 2019
  ident: 4233_CR21
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-12433-w
– volume: 42
  start-page: W478
  year: 2014
  ident: 4233_CR32
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gku377
– volume: 59
  start-page: 492
  year: 2013
  ident: 4233_CR38
  publication-title: Food Chem Toxicol
  doi: 10.1016/j.fct.2013.06.037
– volume: 7
  start-page: 12284
  year: 2017
  ident: 4233_CR50
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-12509-x
– volume: 13
  start-page: 1060
  year: 2022
  ident: 4233_CR17
  publication-title: Chem Sci
  doi: 10.1039/D1SC05613A
– volume: 12
  start-page: 1207
  year: 2021
  ident: 4233_CR69
  publication-title: Food Funct
  doi: 10.1039/D0FO02387F
– volume: 28
  start-page: 235
  year: 2000
  ident: 4233_CR34
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/28.1.235
– volume: 597
  start-page: 4175
  year: 2019
  ident: 4233_CR42
  publication-title: J Physiol
  doi: 10.1113/JP278082
– volume: 28
  start-page: 55
  year: 2013
  ident: 4233_CR66
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfs387
– volume: 2010
  start-page: baq020
  year: 2010
  ident: 4233_CR25
  publication-title: Database (Oxford).
  doi: 10.1093/database/baq020
– volume: 33
  start-page: 1677
  year: 2013
  ident: 4233_CR36
  publication-title: Zhongguo Zhong Xi Yi Jie He Za Zhi
– volume: 8
  year: 2020
  ident: 4233_CR67
  publication-title: Front Bioeng Biotechnol
  doi: 10.3389/fbioe.2020.619252
– volume: 37
  start-page: 217
  year: 2016
  ident: 4233_CR56
  publication-title: Acta Pharmacol Sin
  doi: 10.1038/aps.2015.128
– volume: 70
  start-page: 184
  year: 2017
  ident: 4233_CR71
  publication-title: J Cardiovasc Pharmacol
  doi: 10.1097/FJC.0000000000000504
– volume-title: Idf diabetes atlas
  year: 2021
  ident: 4233_CR1
– volume: 30
  start-page: 1721
  year: 2022
  ident: 4233_CR19
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2022.01.002
– volume: 11
  start-page: 1873
  year: 2020
  ident: 4233_CR7
  publication-title: Diabetes Ther.
  doi: 10.1007/s13300-020-00843-9
– volume: 13
  start-page: 781
  year: 2021
  ident: 4233_CR41
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics13060781
– volume: 9
  start-page: 27
  year: 2020
  ident: 4233_CR54
  publication-title: Antioxidants
  doi: 10.3390/antiox9040273
– volume: 42
  start-page: 227
  year: 2021
  ident: 4233_CR48
  publication-title: Reprod Biomed Online
  doi: 10.1016/j.rbmo.2020.10.003
– volume: 124
  start-page: 2333
  year: 2014
  ident: 4233_CR20
  publication-title: J Clin Invest
  doi: 10.1172/JCI72271
– volume: 139
  start-page: 1101
  year: 1998
  ident: 4233_CR58
  publication-title: Endocrinology
  doi: 10.1210/endo.139.3.5832
– volume: 45
  start-page: 53
  year: 2019
  ident: 4233_CR13
  publication-title: Diabetes Metab
  doi: 10.1016/j.diabet.2018.05.010
– volume: 170
  start-page: 140
  year: 2020
  ident: 4233_CR9
  publication-title: Biochimie
  doi: 10.1016/j.biochi.2020.01.007
– volume: 39
  start-page: 8709
  year: 2012
  ident: 4233_CR61
  publication-title: Mol Biol Rep
  doi: 10.1007/s11033-012-1728-3
– volume: 44
  start-page: D1202
  year: 2016
  ident: 4233_CR30
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkv951
– volume: 16
  start-page: 90
  year: 2023
  ident: 4233_CR37
  publication-title: BMC Med Genomics
  doi: 10.1186/s12920-023-01519-6
– volume: 234
  start-page: 5033
  year: 2019
  ident: 4233_CR47
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.27306
– volume: 15
  start-page: 1154
  year: 2014
  ident: 4233_CR43
  publication-title: ChemBioChem
  doi: 10.1002/cbic.201300754
– volume: 14
  start-page: 176
  year: 2016
  ident: 4233_CR44
  publication-title: J Transl Med
  doi: 10.1186/s12967-016-0922-9
– volume: 25
  start-page: 121
  year: 2018
  ident: 4233_CR3
  publication-title: Adv Chronic Kidney Dis
  doi: 10.1053/j.ackd.2017.10.011
– volume: 37
  start-page: 2864
  year: 2014
  ident: 4233_CR2
  publication-title: Diabetes Care
  doi: 10.2337/dc14-1296
– volume: 9
  start-page: 362
  year: 2019
  ident: 4233_CR18
  publication-title: Biomolecules
  doi: 10.3390/biom9080362
– volume: 5
  start-page: 245
  year: 2018
  ident: 4233_CR70
  publication-title: Genes Dis
  doi: 10.1016/j.gendis.2018.06.001
– volume: 49
  start-page: D394
  year: 2021
  ident: 4233_CR27
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkaa1106
– volume: 11
  start-page: 425
  year: 2020
  ident: 4233_CR15
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2020.00425
– volume: 3
  start-page: 33
  year: 2011
  ident: 4233_CR31
  publication-title: J Cheminform
  doi: 10.1186/1758-2946-3-33
– volume: 30
  start-page: 412
  year: 2002
  ident: 4233_CR26
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/30.1.412
– volume: 4
  start-page: P3
  year: 2003
  ident: 4233_CR29
  publication-title: Genome Biol
  doi: 10.1186/gb-2003-4-5-p3
– volume: 49
  start-page: D480
  year: 2021
  ident: 4233_CR33
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkaa1100
– volume: 16
  start-page: 489
  year: 2020
  ident: 4233_CR6
  publication-title: Nat Rev Nephrol
  doi: 10.1038/s41581-020-0309-2
SSID ssj0024549
Score 2.5956752
Snippet Background Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol...
Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol (RES) for...
Background Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol...
BackgroundDiabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol...
Abstract Background Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 380
SubjectTerms AKT1 protein
Aldehyde Reductase
Analysis
Association analysis
Bioinformatics
Biomedical and Life Sciences
Biomedicine
Care and treatment
Computer simulation
Diabetes
Diabetes Mellitus
Diabetic kidney disease
Diabetic Nephropathies
Diabetic nephropathy
Diagnosis
Dietary supplements
Dosage and administration
ESR1 protein
Experimental validation
Gelatinase A
Gelatinase B
Gene expression
Gene set enrichment analysis
Genes
Genomics
Glucose
Humans
Kidney diseases
Matrix Metalloproteinase 9
Medicine/Public Health
Molecular docking
Molecular Docking Simulation
Network Pharmacology
Nutrition & metabolism
Peroxisome proliferator-activated receptors
Pharmacology
Phytochemicals
PPAR gamma
Proteins
Reproducibility of Results
Resveratrol
Software
Therapeutic applications
Therapeutic targets
SummonAdditionalLinks – databaseName: DOAJ Open Access Full Text
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXxJuUgoyExIGNmsRZJzkWRMWFigOVerOcsSMiuk61u63Un8M_5bPz6KYIuJDDHjK2YnvG81iPv2HsLZwMbTKqY6g-E-eVSGONV7FB9EyFrk1uk1Bsojg5Kc_Oqq87pb58TlgPD9wv3KGl3ENmoUsichKFttJoPKnVVZ6G6-UZvJ4xmBpR9hD2jFdkSnm4gVWDQoB9in0eCH5nZiig9f-uk3eM0u2EyVunpsEYHT9kDwYvkh_1o3_E7lj3mN37MpyTP2E_Tx353Ex05vDw-Mr6C77tZsW7hiPAvvJQyuvunLcu0Kd0c0_v_45tif9ojbPXfDjD4d7gGd457vrUcX5xA3t9veCrsdAuN9Cx-PKCa2f4bgkBDrFu-yJOT9np8advHz_HQzGGmGRSbuNGNlmtc0u2gA4wiV4WjcmMbmprpNDCamkTYai0lFh4IXVWg_Fwx6SgRFopnrE91zn7gnFphVg2IoNz1-RpRhV8DBJ4qCyF1hSxdOSNogGp3BfMOFchYiml6vmpwE8V-KmSiL2f-lz0OB1_bf3Bs3xq6TG2wwtInhokT_1L8iL2zguM8poAwyM9XGjAJD2mljoqlohnE_ibETuYtcQOpjl5FDk1aJCNAq1I00JW-M6biex7-qw4Z7vL0AYBpo_iI_a8l9BpSgKqu6zyKmLlTHZnc55TXPs94IvD51wiDMeHF6OY34zrz4u6_z8W9SW7n4Vt6qtDHbC97frSvmJ36Wrbbtavwyb_BaVsVwA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: SpringerLINK Contemporary 1997-Present
  dbid: RSV
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagINQLb2igICMhcWAjkjjrOMeCqLhQIaCoN8uxHYjoOtXutlJ_Dv-Uz85jm_KQIIccMuP4kXnG4xlCnsPIUCbTVQzRZ-K8ZGms8Cg28J51oSqT2yQUmygODsTRUfmhPxS2GqLdhy3JIKkDWwv-agXNBKaGjol9LAfuV8k1qDvh2fHjpy-bDHtweYbjMb9tN1FBIVP_r_L4gkK6HCx5acc0KKL9W_83hdvkZm940r2OUu6QK9bdJTfe91vr98iPQ6d9OCfeR2EU0oX1Z4Kb1YK2NYVPfuazLy_bY9q4AB8j1D28-4PbaPq9Mc6e037bh3odaWjrqOuizenJJlP2-Ywuhtq81EAso-cZVc7Qi1UHKDih6eo-3SeH-28_v3kX9_UbYs0TsY5rXmeVyq22BcSGSdS8qE1mVF1Zw5liVnGbMKOF1YnFl6yyCrQCC44znXDL2QOy5VpndwjllrF5zTLYg3WeZrqEWaIZLi0EU0pHJB0-qdR9cnNfY-NYBidHcNmtvcTay7D2MonIy7HNSZfa46_Yrz2ljJg-LXd40C6_yp7LpdW5z-8G-k4Yxlcoy43ClVpV5mCLiLzwdCa98MDwtOrPQGCSPg2X3CvmcIETmKgR2Z1ggun1FDxQquyFzkoCVqRpwUv082wE-5Y-kM7Z9jTgwCf1jn9EHnaEPU6JQdqLMi8jIiYkP5nzFOKabyElOczUOTx3dDwbKH8zrj8v6qN_Q39MtrPAPL501C7ZWi9P7RNyXZ-tm9XyaZACPwGpb1rk
  priority: 102
  providerName: Springer Nature
Title Uncovering the mechanism of resveratrol in the treatment of diabetic kidney disease based on network pharmacology, molecular docking, and experimental validation
URI https://link.springer.com/article/10.1186/s12967-023-04233-0
https://www.ncbi.nlm.nih.gov/pubmed/37308949
https://www.proquest.com/docview/2827117695
https://www.proquest.com/docview/2825500172
https://pubmed.ncbi.nlm.nih.gov/PMC10258995
https://doaj.org/article/ec468104e0034c37ae6daaaa1ea94115
Volume 21
WOSCitedRecordID wos001007559500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMedCentral
  customDbUrl:
  eissn: 1479-5876
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0024549
  issn: 1479-5876
  databaseCode: RBZ
  dateStart: 20030101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1479-5876
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0024549
  issn: 1479-5876
  databaseCode: DOA
  dateStart: 20030101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1479-5876
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0024549
  issn: 1479-5876
  databaseCode: M~E
  dateStart: 20030101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1479-5876
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0024549
  issn: 1479-5876
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1479-5876
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0024549
  issn: 1479-5876
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database (subscription)
  customDbUrl:
  eissn: 1479-5876
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0024549
  issn: 1479-5876
  databaseCode: PIMPY
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: Springer
  customDbUrl:
  eissn: 1479-5876
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0024549
  issn: 1479-5876
  databaseCode: RSV
  dateStart: 20030601
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RLUJceD8CZWUkJA40ahJnneSEWtQKDl2tCkXLyXJsByK6zrK7rdSfwz9l7Di7TRG9kEOkxI7iST7Py-MZgDeoZAiVyDJE1qfCtKBxKPBWqNB6lpkoVaojV2wiG4_z6bSYeIfb0odVdjzRMWrVSOsj30PTIIvjjBWj9_Nfoa0aZVdXfQmNLdi2mcrSAWwfHI4nJ5tse2j-dFtlcra3ROmGjAHlVGjjQfDcE0cua__fvPmKcLoeOHlt9dQJpaP7_0vOA7jn1VGy3-LnIdzS5hHcOfYL7o_h96mRNsgT305QVSQzbXcK18sZaSqClvqFzcm8aM5IbVz7Om7dtrd-3VqSn7Uy-pL4xSBiJacijSGmjUEn803-7MtdMusq9hIkw3ryd4kwilytRUBwftRtNagncHp0-OXDx9BXdQgli_JVWLEqKUWqpc6QmahIjLJKJUpUpVaMCqoF0xFVMtcy0qjOlEmJCEK9jlEZMc3oUxiYxujnQJimdFTRBLXEKo0TWaCyIikeMs-pEDKAuPu5XPqU57byxhl3pk_OeAsIjoDgDhA8CuDd-pl5m_Djxt4HFjPrnjZZt7vRLL5zP_e5lqnN-oaojyiOLxOaKYFHrEWR4mQJ4K1FHLcsBYcnhd8ZgUTa5Fx8PxshXCJUXAPY6fVEViD7zR3YuGdFS75BWgCv1832SRteZ3Rz7vqgpWrdAQE8ayG-JomiDMiLtAgg74G_R3O_xdQ_XKJyVF5HaM_ji3e7ebIZ178_6oubyXgJdxM3g20BqR0YrBbn-hXclhererkYwlY2zdw5H3puMHSOFryafDqefMOrk89f_wAUv2vK
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQcCF9yNQwEggDmzUJM46yQGh8qhatV1xaKXeXMd2IKLrLJtt0f4c_gC_kRkn2W2K6K0HcthD7GQ9zsw3M_Z4hpBXYGRIHancB-jTfpyx0Jdwy9fgPatE5jo2gSs2kYxG6eFh9mWF_O7OwmBYZYeJDqh1pXCNfB1cgyQME54N309--Fg1CndXuxIaDVvsmPlPcNnqd9uf4Pu-jqLNz_sft_y2qoCveJDO_IIXUS5jo0wCzKwDOUwKHWlZ5EZzJpmR3ARMq9SowIA6zaMcKAC7gjMVcMMZvPcKuQo4nmAIWXK4dPBicLa6gzkpX69BlwIMgVb0MfoEfnvKz9UI-FsTnFGF58M0z-3VOhW4eft_m7w75FZrbNONRjrukhVj75Hre204wX3y68AqDGEFaikYwnRs8Bx0WY9pVdCpqU8x4_S0Oqalde2LqHxsb1atS0W_l9qaOW23uijaBZpWltomwp5OltnB5wM67uoRU5g23KcYUGk1PVtpgYL0l02tqwfk4FIm6CFZtZU1jwnlhrFhwSKwgYs4jFQGpphicKk0ZVIqj4QdMwnVJnTHuiLHwjl2KRcNAwpgQOEYUAQeebt4ZtKkM7mw9wfk0UVPTEXublTTr6JFNmFUjDntQKYDBuNLpOFawhUamcUABR55gxwuEDBheEq25z6ASEw9JjaSIbBnAGa5R9Z6PQHoVL-5Y27RAm0tlpztkZeLZnwSgwetqU5cH_DDcbHDI48akVqQxEDDpVmceSTtCVuP5n6LLb-5NOxgmg_TDP940Mnlclz_ntQnF5PxgtzY2t_bFbvbo52n5Gbk0ANLZa2R1dn0xDwj19TprKynzx32UHJ02fL6B08DxJk
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BQRUX3oVAASMhcaBRkzjrJMfyWIGAVSUo6s1ybAcius5qd1upP4d_yoyT7G7KQ0LkkEPGWT92nvH4G4Bn6GQok-gyRNVnwrTgcajwUWgwetaZKk1qI19sIptM8uPj4nDjFL_Pdu-3JNszDYTS5Jb7M1O1Ip6L_QVaKRRwtDch5XXg_TJcSaloEMXrn76s0fYw_OmPyvz2vYE58qj9v-rmDeN0MXHywu6pN0rjG_8_nZtwvXNI2UHLQbfgknW3Yftjt-V-B34cOU1pnvjbDJ1FNrV0VrheTFlTMYzVzwiVed6csNp5-ipznejtl91as--1cfacddtBjGynYY1jrs1CZ7M1gvb5Hpv2NXuZQXWNPe8x5QzbrEbAUELqth7UXTgav_n86m3Y1XUItYjyZViJKilVarXNUJ2YSI2yyiRGVaU1gitulbARNzq3OrLo0JRJiTyEnp3gOhJW8B3Yco2z94EJy_mo4gn6iVUaJ7pAd0VzvHSec6V0AHH_90rdgZ5T7Y0T6YOfXMh27SWuvfRrL6MAXqzembWQH39t_ZK4ZtWS4Lr9g2b-VXbSL61OCfcN-T7iOL5MWWEUXrFVRYriEsBz4jlJSgWHp1V3NgInSfBc8iAbYWgcoesawO6gJSoDPST3XCs7ZbSQSMviOBMF9vN0RaY3KcHO2ebUt8FYlT4IBHCvZfLVlDhagbxIiwDyAfsP5jykuPqbhypH93WEET12vNdLwXpcf17UB__W_AlsH74eyw_vJu8fwrXEyxFVl9qFreX81D6Cq_psWS_mj71y-AnvXGas
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Uncovering+the+mechanism+of+resveratrol+in+the+treatment+of+diabetic+kidney+disease+based+on+network+pharmacology%2C+molecular+docking%2C+and+experimental+validation&rft.jtitle=Journal+of+translational+medicine&rft.au=Chen%2C+Shengnan&rft.au=Li%2C+Bo&rft.au=Chen%2C+Lei&rft.au=Jiang%2C+Hongli&rft.date=2023-06-12&rft.eissn=1479-5876&rft.volume=21&rft.issue=1&rft.spage=380&rft_id=info:doi/10.1186%2Fs12967-023-04233-0&rft_id=info%3Apmid%2F37308949&rft.externalDocID=37308949
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon